Skip to main content

Table 6 SUVmax of the liver and lymph nodes, by radioactivity per patient’s body weight

From: A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

Organ Statistic 0.69–0.97 MBq/kg 0.97–1.55 MBq/kg 1.55–2.09 MBq/kg 2.09–3.72 MBq/kg
Liver N 11 6 9 8
Mean ± SD 24.4 ± 9.46 13.8 ± 5.49 16.1 ± 7.25 23.3 ± 17.77
Median (range) 23.8 (15.0–49.0) 12.6 (8.0–22.0) 14.8 (7.0–26.0) 14.1 (10.0–60.0)
Lymph nodes N 5 6 7 8
Mean ± SD 25.5 ± 8.72 34.3 ± 26.46 29.2 ± 15.75 17.9 ± 11.81
Median (range) 21.3 (20.0–41.0) 28.5 (12.0–83.0) 21.7 (13.0–54.0) 13.0 (5.0–36.0)
  1. n corresponds to the number of patients with lesions in either the liver or the lymph nodes
  2. The number of patients with lesions in the primary tumour site and bones was too small (≤ 3 in each category) to allow a meaningful interpretation of PET/CT scans for these organs
  3. CT computed tomography, PET positron emission tomography, SD standard deviation, SUVmax maximum standardised uptake value